Neovascular Age Related Macular Degeneration clinical trials

Explore recruiting neovascular age related macular degeneration clinical trials.

Recruiting neovascular age related macular degeneration studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neovascular Age Related Macular Degeneration trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, single-arm, open-label extension study (A-FAN)

Austria

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase IIIb/IV, Multicenter, Randomized, Open-Label, Two-Arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 Weeks in Patients with Neovascular Age-Related Macular Degeneration (CONSTANCE)

Germany, Italy, Spain, France

Phase III and phase IV (Integrated) EU CTIS Study details

A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy

Italy, Hungary, France, Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)

Germany, Italy, France, Hungary, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)

Czechia, Portugal, Hungary, Spain, Belgium, Italy +7 more

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

Hungary, Denmark, Czechia, Poland, Latvia, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neovascular Age Related Macular Degeneration trials by city

Neovascular Age Related Macular Degeneration clinical trials

Recruiting neovascular age related macular degeneration studies right now

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

Progression Suppression and Retinal Regression in VEGF-resistant AMD

Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Also recruiting in Europe

Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, single-arm, open-label extension study (A-FAN)

A Phase IIIb/IV, Multicenter, Randomized, Open-Label, Two-Arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 Weeks in Patients with Neovascular Age-Related Macular Degeneration (CONSTANCE)

A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)

A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age Related Macular Degeneration trials by city

Other conditions